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Abstract
Variation in the zinc finger-binding domain (ZFBD) of the protein PR Domain-Containing Protein 9 (PRDM9) is
associated with altered placement of recombination in the human genome. As both the absence and altered
placement of recombination are observed among chromosomes 21 that nondisjoin, we genotyped the PRDM9 ZFBD
among mothers of children with Trisomy 21 in efforts to determine if variation within this region is associated with the
recombination-related risk for chromosome 21 nondisjunction (NDJ). In our approach, PCR was used to amplify the
ZFBD of PRDM9 and products were then subjected to bi-directional Sanger sequencing. DNA sequencing reads
were aligned and compared to the sequence of the PRDM9 alleles previously identified. Chi-Square analysis was
used to compare allele frequencies between cases (N=235, mothers of children with maternally-derived Trisomy 21)
and controls (N=48, fathers of children with maternally-derived Trisomy 21). Results of our analysis showed that the
frequency of PRDM9 ZF minor alleles is significantly increased among women displaying NDJ of chromosome 21
and no recombination on 21q (p=0.02). Even more, when compared to those for the PRDM9 major A-allele, these
minor alleles displayed fewer predicted binding sites on 21q. These findings suggest that allelic variation in the ZF of
PRDM9 may play a role in the risk for chromosome 21 NDJ by leading to reduced recombination on 21q.
Keywords: Nondisjunction; PRDM9; Recombination; Down
syndrome; Zinc finger; Aneuploidy
Introduction
PR Domain-Containing Protein 9 (PRDM9) is exclusively expressed
during early meiosis in both males and females [1]. Deletions of the
gene in mice results in the production of gametes blocked at pachytene
of meiosis I that display a reduced number of Dmc1 loci, a protein that
localizes to the sites of meiotic crossovers [1]. The human consensus
PRDM9 allele (the major allele, also known as the A-allele) binds a 13
bp motif enriched at human LD-based hotspots, namely,
CNCCNTNNCCNC [2]. Further, allelic variation in the ZF (zinc
finger) of PRDM9 is significantly associated with differential hotspot
usage in humans [3,4]. Carriers of PRDM9 minor alleles display
reduced recombination in LD-based hotspots [3]; interestingly, this is
not necessarily indicative of reduced rates of genome-wide
recombination, but rather the altered placement of recombination [5].
Thus the placement of recombination and the hotspots they give rise
to, vary by PRDM9 ZF allele. Collectively, these findings explain, at
least in part, the molecular basis for the distribution of meiotic
recombination in mammals in which the binding of PRDM9 to specific
sequences in the genome targets the initiation of recombination at
specific locations in the genome.
The number and placement of recombinant events differ
significantly between chromosomes 21 that segregate normally and
those that nondisjoin. [6-8]. Thus we questioned whether variation in
the ZF of PRDM9 was also associated with the recombination-related
risk for chromosome 21 nondisjunction (NDJ). Results of our analysis
showed that the frequency of PRDM9 ZF minor alleles is significantly
increased among women displaying NDJ of chromosome 21 and no
recombination on 21q (p=0.02). Even more, when compared to those
for the PRDM9 major A-allele, these minor alleles displayed fewer
predicted binding sites on 21q. These findings suggest that allelic
variation in the ZF of PRDM9 may play a role in the risk for
chromosome 21 NDJ by leading to reduced recombination on 21q.
Materials and Methods
Ethical standards
The work presented in this publication was approved by the Emory
University Institutional Review Board. All participants provided
written consent, which indicated that the individuals agreed for study
personnel to proceed with the interview and consented for biological
specimens to be obtained from them and their child. All information
obtained during participant interviews and related to sample collection
were catalogued electronically and de-identified. All procedures
performed in studies involving human participants were in accordance
with the ethical standards of the institutional and/or national research
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committee and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
Study sample
Mothers of children with Down syndrome
Parents of infants with full trisomy 21 were recruited through a
multisite study of risk factors associated with chromosome mal-
segregation [9,10]. Parents and individuals with trisomy 21 donated a
biological sample (either blood or buccal) from which DNA was
extracted. Information on race was self-reported by the mother
through an interview. For this study, only those reporting as Caucasian
were included to reduce population stratification.
Determining stage and origin of meiotic chromosome mal-
segregation
Samples were genotyped at 1536 SNP loci on 21q by the Center for
Inherited Disease Research using the Illumina Golden Gate Assay. The
most centromeric single nucleotide polymorphism (SNP) was
rs2259403 and the most telomeric was rs46909248. In order to assess
the quality of our genotyping data, Mendelian inconsistencies and
sample mix-ups were identified using RelCheck among the trios. In
addition, parental genotyping data were used to identify poorly
performing SNPs. SNPs that met the following criteria were excluded
from our analyses: minor allele frequency (MAF)<0.01, deviation from
Hardy Weinberg Equilibrium (HWE) (p<0.01), heterozygosity>0.60 or
>10% missingness. We also excluded SNPs on a family-by-family basis
if >50% of the genotype data for a proband had low intensity levels.
The parental origin of the meiotic error was determined by
establishing the contribution of parental alleles to the proband with
trisomy 21. Only cases of maternal origin were included in our
analyses. Once the maternal origin of the meiotic error was
established, markers located in the pericentromeric region (13,615,252
bp–16,784,299 bp) of 21q were used to infer the stage of the meiotic
error, meiosis I (MI) or meiosis II (MII). If parental heterozygosity was
retained in the trisomic offspring, we concluded an MI error. If
parental heterozygosity was reduced to homozygosity, we concluded an
MII error. In this assay, we cannot distinguish between the different
types of underlying errors that might lead to these specific errors. For
example, an error that is initiated in MI and not resolved properly in
MII leads to the contribution of sister chromatids to the gamete and
would be inferred as a MII error. Sister chromatids that prematurely
separate in MI will sometimes lead to an “MI” error and other times to
an “MII” error depending on the segregation of the chromatids at MI.
Lastly, when all informative markers in the parent of origin were
reduced to homozygosity, the origin of NDJ was inferred to be a post-
zygotic, mitotic error and excluded from the study.
Identification of the number and location of recombination
along nondisjoined chromosomes 21
Recombination breakpoints were defined by switches from
nonreduction (N) or reduction (R) or vice versa of maternal
heterozygosity to proband homozygosity for each marker along the
nondisjoined chromosome 21 (e.g. NNNNNNNNNNRRRRRRRRRR).
In this example, the location of neighbouring markers indicating the
first change from N to R (highlighted in bold) would indicate the
location of our recombination breakpoints. In order to ensure that the
switch from nonreduction to reduction or vice versa was not due to a
genotyping error, a minimum of either one informative STR or eight
consecutive informative SNPs flanking the recombination breakpoint
were required (the example for informative SNPs is shown above). An
exception to this rule occurred when the most proximal or distal
informative markers on 21q indicated the presence of recombinant
event. In these instances, a minimum of either one informative STR or
four consecutive informative SNPs were required to define the
breakpoints of recombination (e.g. NNNNNNNNRRRR-telomere).
Euploid samples – controls
Fathers of children with full trisomy 21 due to a maternal error, who
also self-report as Caucasian served as controls for this analysis. These
samples were used to establish the PRDM9 ZF allele frequency
distribution among normally segregating chromosomes 21. Our
analyses that focus on the placement of recombination are case-only
analyses, as we did not have information on the placement of
recombination in these male controls and because male recombination
differs significant from that in females in general with respect to
number and location of events [11].
Sequencing and allele classification for cases
PCR using previously published primers (PN1.2F
TGAATCCAGGGAACACAGGC, PN2.4R
GCAAGTGTGTGGKGACCACA [3] was used to amplify the ZFBD of
PRDM9 (224589817:23507724-23528706 Homo sapiens chromosome
5, GRCh37.p5 Primary Assembly). PCR products were run on a 2%
agarose gel to:1) verify successful amplification and 2) to determine
zinc finger (ZF) repeat number genotype. Based on the location of the
primers, a sample with 13 ZF repeats would be 1305 bp long with the
size of the PCR product increasing in 84 bp increments with each
additional zinc-finger repeat. Bi-directional Sanger sequencing of these
PCR products was conducted in order to obtain the sequence for the
entire ZFBD. DNA sequencing reads were aligned and compared to
ZFBD allele sequences identified by Berg et al. [3] (Genbank Accession
numbers HM210983–HM211006) in order to characterize the
distribution of PRDM9 ZFBD alleles amongst our population of cases
and controls. Assuming Hardy Weinberg equilibrium, 74% if the
population should be homozygous for the A-allele, 24% should be
heterozygous and 2% should be non-carriers of the A-allele. In
instances where individuals were heterozygous for the ZFBD allele, the
allele type had to be inferred by assuming that individuals were
carriers of one A-allele. Based on the variation, the sequence of the
other allele was identified. In instances where the sequence did not
provide evidence that one A-allele was present, the specific allele types
were not identified, but the sample was classified as carrying two non
A-alleles.
Identifying the location of prdm9 predicted binding
sequences on chromosome 21
In order to identify the sequence of DNA bound by PRDM9 minor
alleles, the PRDM9 ZF DNA sequence was translated to an amino acid
sequence using the ExPASy - Translate tool. The DNA sequence bound
by each ZF allele was determined using a DNA-binding site predictor
for Cys2His2 Zinc Finger Proteins [12]. Briefly, given C2H2 zinc finger
protein, this program predicts a position weight matrix representing its
DNA binding specificity and displays it as a sequence logo. The
sequence logo represents each column of the alignment by a stack of
letters, with the height of each letter proportional to the observed
frequency of the corresponding amino acid or nucleotide, and the
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overall height of each stack proportional to the sequence conservation,
measured in bits, at that position. The letters of each stack are ordered
from most to least frequent, so that one may read the consensus
sequence from the tops of the stacks. In cases positions where the
sequence is not conserved as indicated by a bit quantity <1.0 or ~50%
the height of each nucleotide within the logo, the nucleotide call was
considered unknown and assigned a call of “N”. The physical location
of each binding sequence on 21q was identified using the Short Match
Feature from the UCSC Genome Browser. Genotypes used to establish
the predicted binding sequences for normally segregating
chromosomes were mothers of French Canadian descent with at least
two children. Data for the PRDM9 ZF allele distribution among this
population were taken from Hussein et al. [13].
Statistical analyses
Cases were stratified by the stage of the NDJ error, meiosis I (MI) or
meiosis II (MII), and chi square analysis was used to compare the allele
frequencies between controls and several etiologically-defined
subgroups of cases. A 95% confidence interval was calculated for the
major allele frequency for each outcome group. Logistic regression was
used to compare allele frequencies between subgroups while
controlling for maternal age.
Results
The primary goal of the present study was to determine if variation
in the ZF of PRDM9 is associated with the NDJ of chromosome 21.
The PRDM9 ZF genotype and allele distributions for cases and controls
can be found in Table 1. Over 29 PRDM9 ZF alleles have already been
identified among the European population with the major allele (the
A-allele) having a frequency of approximately 86% [14]. Our controls,
also of European descent, displayed a similar major allele frequency,
84%. This value is comparable to the major A-allele frequency
calculated using the raw data from Hussein et al. [13] which estimated
the major A-allele frequency among Caucasian women of euploid
children to be ~84%. Interestingly, we did find evidence for an excess
of minor alleles among MI cases with no recombination on 21q (Table
1). The point estimate for the major allele frequency among MI cases
with no recombination on 21q was 0.68 or 68%.
Outcome Group A/A A/N N/N
Number of
participants







Zero Recombinants 0.53 0.3 0.17 87 0.68 0.58 0.78
1 Recombinant 0.65 0.33 0.02 66 0.82 0.73 0.91
>1 Recombinant 0.67 0.25 0.08 12 0.79 0.56 1.02
MII errors
1 Recombinant 0.65 0.3 0.06 54 0.8 0.69 0.9
>1 Recombinant 0.69 0.31 0 16 0.84 0.67 1.02
Controls 0.73 0.23 0.04 48 0.84 0.74 0.95
Table 1: Distribution of PRDM9 genotypes stratified by meiotic stage and number of recombinants.
In order to determine if variation in the ZF of PRDM9 was
associated with the NDJ of chromosome 21, cases and controls were
separated into non-carriers (individuals with the AA genotype) and
carriers of PRDM9 ZF minor alleles (individuals with AN or NN
genotype where “N” represents any of the previously identified ZF
minor alleles [3,13]). Chi-square analysis was then used to determine if
the distribution of carriers and non-carriers of minor alleles differed
between cases and controls. The only significant difference detected
was between controls and MI cases with no observed recombination
on 21q (p=0.03, Table 2). Data from logistic regression models
suggested that women from this outcome group (i.e. MI cases with no
recombination on 21q) were 2.45 times more likely to be carriers of at
least one minor allele than controls (Table 3, p=0.02, 95% CI=1.17,
5.40).
Outcome Group Non Carriers Carriers Total P value
MI Zero Recombinants 46 41 87 0.04
MI One Recombinant 43 23 66 0.5
MI>1 Recombinant 8 4 12 0.94
MII One Recombinant 35 19 54 0.51
MII>1 Recombinant 11 5 16 1
Controls 35 13 48 reference group
Table 2: Distribution of carriers and non-carriers of PRDM9 minor
alleles.
Group Odds Ratio P Value 95% CI
Control N/A Reference Group N/A
MI Zero Recombinants 2.45 0.02 1.17, 5.40
MI One Recombinant 1.51 0.32 0.68, 3.44
MII One Recombinant 1.67 0.22 0.68, 3.67
Table 3: Comparing the odds of being a carrier of minor alleles
between cases and controls.
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As MI cases with no observed recombinants on 21q displayed an
increased frequency of carriers of PRDM9 ZF minor alleles, it was
possible that minor alleles among this population contained fewer
binding motifs on 21q that are recognized by PRDM9. This could lead
to reduced recombination on 21q, a major risk factor for the NDJ of
chromosome 21. This led us to examine the frequency of PRDM9
predicted binding sites on 21q for the major A-allele as well as for
minor alleles detected among MI 0 cases (MI cases displaying no
recombination on 21q) that were carriers of one major allele and one
minor allele. We decided to focus on this population as recent findings
suggest that an interaction between PRDM9 major and minor alleles
affects PRDM9 binding activity and thus hotspot activity [5]. Results
from this analysis showed that the L24 and L9 alleles and alleles with
the same predicted binding sequence as the L24 and L9 alleles (here
designated N2 alleles) were most frequently observed among MI 0
cases heterozygous for the PRDM9 Major A-allele (Table 4). In
addition, there appeared to be fewer binding sequences on 21q for the









L20* 1 1 CCGCCNCGNCCNC *
L24,L9**** 8 CCGCCGTGNCCNC 7
N ** 6 CCGCCGTNNCCNC 36
O1 2 CCGCCGGGNCCNC 16
O2*** 1 CGGTTAGCGTGNC 0
O3 1 CGGCCGTGNCCNC 7
O4 1 CGGCCGGGNCCNC 10




L33 1 CCGCCGTGNCCNC 6
L34 1 CCGCCGTGNCCNC 6
N2**** 6 CCGCCGTGNCCNC 7
Table 4: PRDM9 ZF alleles detected among MI zero cases heterozygous
for the PRDM9 major A allele.
The predicted binding sequence for PRDM9 major A-allele is
CCGCCGTNNCCNC. The values indicted under the columns labelled
cases and controls represent the number of heterozygous carriers of the
major A-allele. The minor allele for these samples and its predicted
binding-sequence is indicated.
* The L20 PRDM9 ZF allele had >100 predicted binding sequences
on 21q.
**Samples heterozygous for the major A-allele that contain a minor
allele that has a predicted binding sequence identical to the PRDM9
major-A-Allele. These alleles have not been previously reported by
previous studies.
*** The O2 and C alleles had no predicted binding sequences on 21q.
****Samples heterozygous for the major A-allele that contain a minor
allele that has a predicted binding sequence identical to the PRDM9
L24 allele.
Discussion
We found that the frequency of the PRDM9 ZF major allele, also
referred to as the A-allele, was approximately 0.84 among controls.
This finding is important for two reasons; first it provides an
independent estimate of the PRDM9 major A-allele frequency that is
comparable to studies that also examined samples of northern
European ancestry [3,13]. Second, it provides confidence that our
method of inferring alleles, which differed from that of others [3,13],
correctly identified major and minor alleles among our cases and
controls.
We did not find evidence for an increased frequency of PRDM9
minor alleles among MI and MII cases exhibiting only one
recombinant event on 21q. This however does not mean that minor
alleles are not implicated in the altered placement of recombination on
21q. In order to address this question our future aims entail increasing
our population size. This will enable us to limit our analysis of MI and
MII cases to only include those that display recombination within the
most distal 3.2 and proximal 6.5 Mb of 21q, regions where
recombination is significantly increased among MI and MII errors
respectively. Only 28% of MI cases are estimated to display a single
recombinant event on 21q [14] and while a significant subset of these
cases will display altered patterns of recombination, the overall
proportion of MI singles is low which prevents us from examining the
relationship between the altered placement of recombination on 21q,
PRDM9 minor alleles and the risk for the NDJ of chromosome 21 at
this time. The absence of recombination on 21q however is observed in
approximately 45% of all maternal meiotic cases of trisomy 21 [14].
Interestingly not only did we find an increased frequency of PRDM9
minor alleles among this population, the minor alleles detected among
MI 0 cases displayed fewer predicted binding sites on 21q. This
observation is consistent with our hypothesis that the reduction in
recombination on 21q observed among nondisjoined chromosomes 21
is caused by reduced PRDM9 binding. However, as only ~40% of LD-
based hotspots display the 13 bp motif predicted to be bound by the
PRDM9 consensus allele, the strength of this support depends greatly
on the chromosome 21 specific relationship between LD-based hotspot
and binding sequence location.
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